Imeglimin improves systemic metabolism by targeting brown adipose tissue and gut microbiota in obese model mice
Imeglimin is a recently developed anti-diabetic drug that could concurrently promote insulin secretion and insulin sensitivity, while its mechanisms of action are not fully understood. Here we show that imeglimin administration could protect mice from high fat diet-induced weight gain with enhanced energy expenditure and attenuated whitening of brown adipose tissue. Imeglimin administration led to significant alteration of gut microbiota, which included an increase of Akkermansia genus, with attenuation of obesity-associated gut pathologies.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Motoharu Awazawa, Maya Matsushita, Ikumi Nomura, Naoki Kobayashi, Miwa Tamura-Nakano, Yuriko Sorimachi, Keiyo Takubo, Kohjiro Ueki Tags: Brief Report Source Type: research
More News: Biomedical Science | Diabetes | Diets | Eating Disorders & Weight Management | Endocrinology | Expenditures | High Fat | Insulin | Nutrition | Obesity